Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604680 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 509
- Enrollment target
- 20
- Study locations
NCT02604680 is a Phase 2 study of Acne Vulgaris that has completed, run by Braintree Laboratories. The registered enrollment target is 509 participants, above the 268-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (90% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02604680, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 509 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of the study is to compare the safety and efficacy of multiple formulations of BLI1100 to a control group and placebo in treating patients with moderate-severe acne vulgaris.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BLI1100-1
- DRUG BLI1100-2
- DRUG BLI1100-3
- DRUG BLI1100-4
Study Locations (20)
Florida
- BLI Research Site 19 - Hialeah
- BLI Research Site 49 - Jupiter
- BLI Research Site 12 - Miami
- BLI Research Site 54 - Miami Lakes
- BLI Research Site 20 - Ormond Beach
- BLI Research Site 59 - Port Saint Lucie
- BLI Research Site 15 - St. Petersburg
- BLI Research Site 1 - Tampa
- BLI Research Site 29 - Tampa
California
- BLI Research Site 57 - Chula Vista
- BLI Research Site 56 - Costa Mesa
- BLI Research Site 18 - Encino
- BLI Research Site 7 - Fremont
- BLI Research Site 45 - Upland
Alabama
- BLI Research Site 27 - Birmingham
- BLI Research Site 24 - Mobile
Colorado
- BLI Research Site 41 - Denver
- BLI Research Site 39 - Wheat Ridge
Arizona
- BLI Research Site 51 - Tucson
Arkansas
- BLI Research Site 40 - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02604680
The ClinicalTrials.gov registry entry for NCT02604680 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 268-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (90% higher). The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02604680 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT02604680 about?
NCT02604680 is a clinical study titled "A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris". The objective of the study is to compare the safety and efficacy of multiple formulations of BLI1100 to a control group and placebo in treating patients with moderate-severe acne vulgaris.
What is the current status of trial NCT02604680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 509 participants. The study started on 2015-10. Estimated completion is 2016-06.
What conditions does trial NCT02604680 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02604680?
The interventions under investigation include: Placebo (DRUG), BLI1100-1 (DRUG), BLI1100-2 (DRUG), BLI1100-3 (DRUG), BLI1100-4 (DRUG).
Who is sponsoring clinical trial NCT02604680?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02604680 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.